Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes
Effect of Prandial Treatment With Insulin Glulisine Compared to Regular Human Insulin on Postprandial Endothelial Function and Microvascular Stress in Type 2 Diabetic Patients
The primary objective of the study is to evaluate the postprandial time course of nitrotyrosine after injection of insulin glulisine compared with regular human insulin.
The secondary objectives are to evaluate the postprandial time course of the following efficacy parameters after injection of insulin glulisine compared with regular insulin on
- Blood Glucose
- Insulin
- Intact proinsulin
- Asymmetric dimethylarginine (ADMA)
- Metal matrix proteasis (MMP-9)
- Oxidative status (per ox)
- Interleukin 18 (IL-18)
- Free fatty acids (FFA)
- Oxidised LDL (ox-LDL)
- Microvascular blood circulation measured with laser Doppler at 37 °C (LDF37)
- Microvascular blood circulation measured with laser Doppler at 44 °C (LDF44)
調査の概要
詳細な説明
Phase III b Indication Type 2 Diabetes Trial Objectives 1) Primary objective: The primary objective of the study is to evaluate the postprandial time course of nitrotyrosine after injection of insulin glulisine compared with regular human insulin. 2) Secondary objectives: The secondary objectives are to evaluate the postprandial time course of blood glucose, insulin, intact proinsulin, asymmetric dimethylarginine (ADMA), metal matrix proteasis (MMP-9), free fatty acids (FFA), oxidised LDL (ox-LDL), oxidative status (per ox), IL-18 as well as postprandial time course of microvascular blood circulation measured with laserdopplerflux at 37 °C (LDF37) and 44 C (LDF44).
Efficacy Variables Primary efficacy variablePostprandial time course of nitrotyrosineSecondary efficacy variablePostprandial time course of glucose, insulin, intact proinsulin, ADMA, MMP-9, FFA, ox-LDL, per-ox, and IL-18 as well as postprandial time course of laserdopplerflux at 37 °C and 44 °C Safety Variables Incidence and frequency of adverse events and evaluation of safety laboratory parameters Medication/Dosage Insulin glulisine, dose 0.10 U/kg and Regular Human Insulin, dose 0.10 U/kg Study Duration Duration of study participation for one patient: 5 - 43 days Overall duration of the study: 6 months Design Single-centre, open label, randomized, 2-way-crossover trial Population Male and female type 2 diabetic patients between 40 and 70 years with HbA1c between 6.5 % and 9.9 % and treated with sulfonyurea alone or in combination with Metformin in a stable dosage within the last 3 months Sample Size N = 15
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Rhineland-Palatinate
-
Mainz、Rhineland-Palatinate、ドイツ、55116
- Ikfe
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Type 2 Diabetes mellitus according to the ADA criteria
- HbA1c between 6.5 % and 9.9 %
- Monotherapy with sulfonylurea or combined with Metformin in a stable dosage within the last 3 months
- Age between 40 and 70 years
- BMI < 40
Exclusion Criteria:
- Type 1 Diabetes mellitus
- Pre-Treatment with insulin within the last 6 months prior to screening
- Treatment with glitazones within the last 6 months prior to screening
- Pre-Treatment with PPARy-agonists, glinides or glucosidase inhibitors within the last 4 weeks prior to screening
- Untreated hypertension stage II-III according to WHO criteria
- Planned or anticipated change in antidiabetic and/or concomitant medication during study participation
- Total Cholesterol > 300 mg/dl (anamnestically)
- Hypokalemia (K < 3.5 mmol /l)
- Major micro- or macrovascular complications as judged by the investigator
- Tobacco use within the last 12 months prior to screening
- Drugs with major impact on endothelial function like nitrates etc.
- History of drug or alcohol abuse within the last five years prior to screening
- Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures
- History of severe or multiple allergies
- Treatment with any other investigational drug within 3 months prior to screening
- Progressive fatal disease
- History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (creatinine > 1.1 mg/dL in women, > 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator
- Pregnancy or breast feeding
- Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner
- Lack of compliance or other similar reason, that according to investigator, precludes satisfactory participation in the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:1
One Day Treatment with Insulin Glulisine
|
100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
他の名前:
|
|
アクティブコンパレータ:2
One day Treatment with Human insulin
|
100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
the postprandial time course of nitrotyrosine after injection of insulin glulisine compared with regular human insulin
時間枠:1 day
|
1 day
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
postprandial time course of blood glucose, insulin, intact proinsulin, ADMA, MMP-9, FFA, ox-LDL, per ox Status, IL-18, postprandial time course of microvascular blood circulation measured with laserdopplerflux at 37 °C and 44 C
時間枠:1 day
|
1 day
|
協力者と研究者
捜査官
- 主任研究者:Thomas A Forst, Prof, MD、Institute for Clinical Research and Development
研究記録日
主要日程の研究
研究開始
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- APIDR_L_01896
- EudraCT Number 2006-005127-42
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。